Tech Company Financing Transactions
Marker Therapeutics Funding Round
On 10/19/2026, Marker Therapeutics secured $2.6 million in funding from private investors.
Transaction Overview
Company Name
Announced On
10/19/2026
Transaction Type
Debt
Amount
$2,600,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will support a Phase 1 clinical study evaluating the Company's lead investigational MAR-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd. TMC Partners Office 1.311
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Website
Email Address
Overview
Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood cancers and solid tumors. Our team is comprised of talented and passionate professionals with deep expertise in cancer immunotherapy and driven by an urgency to deliver effective treatments to patients who currently have few or no therapeutic options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Juan Vera
Chief Operating Officer
Patricia Allison
VP - Human Resources
Edmund Cheung
VP - Regulatory Affairs
Mary Newman
Browse more venture capital transactions:
Prev: 10/19/2026: Prism Data venture capital transaction
Next: 10/19/2026: Huppa venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs